Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...
The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback